Michelle A. Kendall

2.4k total citations
37 papers, 1.4k citations indexed

About

Michelle A. Kendall is a scholar working on Epidemiology, Infectious Diseases and Emergency Medicine. According to data from OpenAlex, Michelle A. Kendall has authored 37 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Epidemiology, 13 papers in Infectious Diseases and 11 papers in Emergency Medicine. Recurrent topics in Michelle A. Kendall's work include HIV-related health complications and treatments (11 papers), Tuberculosis Research and Epidemiology (7 papers) and HIV Research and Treatment (6 papers). Michelle A. Kendall is often cited by papers focused on HIV-related health complications and treatments (11 papers), Tuberculosis Research and Epidemiology (7 papers) and HIV Research and Treatment (6 papers). Michelle A. Kendall collaborates with scholars based in United States, South Africa and Brazil. Michelle A. Kendall's co-authors include Judith S. Currier, Howard N. Hodis, Beverly Alston‐Smith, Theodoros Kelesidis, Otto O. Yang, Francesca J. Torriani, W. Keith Henry, Yanjie Li, Xingye Wu and Pablo Tebas and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Michelle A. Kendall

36 papers receiving 1.3k citations

Peers

Countries citing papers authored by Michelle A. Kendall

Since Specialization

Citations

This map shows the geographic impact of Michelle A. Kendall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle A. Kendall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle A. Kendall more than expected).

Fields of papers citing papers by Michelle A. Kendall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle A. Kendall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle A. Kendall. The network helps show where Michelle A. Kendall may publish in the future.

Co-authorship network of co-authors of Michelle A. Kendall

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle A. Kendall. A scholar is included among the top collaborators of Michelle A. Kendall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle A. Kendall. Michelle A. Kendall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Integrated transcriptome and cell phenotype analysis suggest involvement of PARP1 cleavage, Hippo/Wnt, TGF-β and MAPK signaling pathways in ovarian cancer cells response to cannabis and PARP1 inhibitor treatment 2024 ·Frontiers in Genetics ·Nurit Shalev, Michelle A. Kendall, Navin Kumar, Sudeep Tiwari, Seegehalli M. Anil, Hagit Hauschner, (unknown), (unknown), Eduard Belausov, Bruce E. Kendall, Hinanit Koltai	0
2	A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome 2019 ·International Journal of Infectious Diseases ·(unknown), Barbara Graham, Kristofor J. Webb, Laura V. Ashton, Marisa Harton, Annie Luetkemeyer, (unknown), Reem Al-Mubarak, Sebabrata Mahapatra, (unknown), Michelle A. Kendall, Diane V. Havlir, John T. Belisle, Mary Ann De Groote	20
3	Pregnancy outcomes among HIV-infected women who conceived on antiretroviral therapy 2018 ·PLoS ONE ·Elizabeth M. Stringer, Michelle A. Kendall, Shahin Lockman, Thomas Campbell, Karin Nielsen‐Saines, Fred Sawe, Susan Cu‐Uvin, Xingye Wu, Judith S. Currier	51
4	Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus 2018 ·Medicine ·Theodoros Kelesidis, Michelle A. Kendall, Ann Danoff, Judith A. Aberg, Judith S. Currier, Ann Marie Schmidt	2
5	Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis 2017 ·Journal of Clinical Medicine ·Sharlaa Badal‐Faesen, Cynthia Firnhaber, Michelle A. Kendall, Xingye Wu, Beatriz Grinsztejn, Rodrigo Escada, (unknown), Evelyn Hogg, Ian Sanne, Pamela Johnson, David Alland, Gerald H. Mazurek, Debra Benator, Anne F. Luetkemeyer	8
6	Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332 2016 ·Inflammation ·Ann Danoff, Michelle A. Kendall, Judith S. Currier, Theodoros Kelesidis, Ann Marie Schmidt, Judith A. Aberg	4
7	Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings 2016 ·Clinical Infectious Diseases ·Anne F. Luetkemeyer, Cynthia Firnhaber, Michelle A. Kendall, Xingye Wu, Gerald H. Mazurek, Debra Benator, Roberto C. Arduino, (unknown), Elizabeth Guy, Pamela Johnson, Beverly Metchock, Fred R. Sattler, Edward E. Telzak, Yun F. Wang, Marc Weiner, Susan Swindells, Ian Sanne, Diane V. Havlir, Beatriz Grinsztejn, David Alland	58
8	Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study 2015 ·BMC Infectious Diseases ·John A. Crump, Xingye Wu, Michelle A. Kendall, Prudence Ive, Johnstone J. Kumwenda, Beatriz Grinsztejn, Ute Jentsch, Susan Swindells	14
9	Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults 2013 ·Lipids in Health and Disease ·Theodoros Kelesidis, Otto O. Yang, Michelle A. Kendall, Howard N. Hodis, Judith S. Currier	19
10	Perturbations of Circulating Levels of RANKL-Osteoprotegerin Axis in Relation to Lipids and Progression of Atherosclerosis in HIV-Infected and -Uninfected Adults: ACTG NWCS 332/A5078 Study 2013 ·AIDS Research and Human Retroviruses ·Theodoros Kelesidis, Michelle A. Kendall, Otto O. Yang, Howard N. Hodis, Judith S. Currier	13
11	Biomarkers of Microbial Translocation and Macrophage Activation: Association With Progression of Subclinical Atherosclerosis in HIV-1 Infection 2012 ·The Journal of Infectious Diseases ·Theodoros Kelesidis, Michelle A. Kendall, Otto O. Yang, Howard N. Hodis, Judith S. Currier	167
12	Hepatotoxicity and Gastrointestinal Intolerance When Healthy Volunteers Taking Rifampin Add Twice-Daily Atazanavir and Ritonavir 2009 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·David W. Haas, Susan L. Koletar, (unknown), Michelle A. Kendall, (unknown), John G. Gerber, Andrew Zolopa, Richard Bertz, Michael Child, Lara Hosey, Beverly Alston‐Smith, Edward P. Acosta	50
13	Low Rate of CMV End-Organ Disease in HIV-Infected Patients Despite Low CD4+ Cell Counts and CMV Viremia: Results of ACTG Protocol A5030 2009 ·HIV Clinical Trials ·David A. Wohl, Michelle A. Kendall, Janet Andersen, Clyde S. Crumpacker, Stephen A. Spector, Judith Feinberg, Beverly Alston‐Smith, Susan Owens, (unknown), Michael R. Marco, Sharon Maxwell, Nell S. Lurain, Douglas A. Jabs, Constance A. Benson, (unknown), Mark Z. Jacobson, (unknown)	32
14	Progression of carotid artery intima–media thickening in HIV-infected and uninfected adults 2007 ·AIDS ·Judith S. Currier, Michelle A. Kendall, W. Keith Henry, Beverly Alston‐Smith, Francesca J. Torriani, Pablo Tebas, Yanjie Li, Howard N. Hodis	107
15	Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV 2007 ·AIDS ·Grace A. McComsey, Michelle A. Kendall, Pablo Tebas, Susan Swindells, Evelyn Hogg, Beverly Alston‐Smith, (unknown), Geetha Gopalakrishnan, Constance A. Benson, David A. Wohl	119
16	A reduced frequency visit schedule underreports adverse events that resulted in dose modifications or treatment discontinuations in HIV/AIDS clinical trials: ACTG DACS 207 2006 ·Contemporary Clinical Trials ·Michelle A. Kendall, Janet W. Andersen, Charles van der Horst	4
17	Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers 2005 ·Clinical Pharmacology & Therapeutics ·Marshall J. Glesby, Judith A. Aberg, Michelle A. Kendall, Carl J. Fichtenbaum, Richard Hafner, S HALL, (unknown), Andrew Zolopa, J G Gerber	69
18	The Safety of Discontinuation of Maintenance Therapy for Cytomegalovirus (CMV) Retinitis and Incidence of Immune Recovery Uveitis Following Potent Antiretroviral Therapy 2005 ·HIV Clinical Trials ·David A. Wohl, Michelle A. Kendall, Susan Owens, Gary N. Holland, Mostafa Nokta, Stephen A. Spector, Rachel Schrier, Susan A. Fiscus, Malcolm E. Davis, Mark Z. Jacobson, Judith S. Currier, K. Squires, Beverly Alston‐Smith, Janet Andersen, William R. Freeman, Mark Higgins, Francesca J. Torriani, (unknown)	28
19	The predictive value of cytologic testing in women with the human immunodeficiency virus who have low-grade squamous cervical lesions: A substudy of a randomized, phase III chemoprevention trial 2003 ·American Journal of Obstetrics and Gynecology ·William R. Robinson, (unknown), Michelle A. Kendall, Teresa M. Darragh	11
20	Cytomegalovirus (CMV) and Human Immunodeficiency Virus (HIV) Burden, CMV End-Organ Disease, and Survival in Subjects with Advanced HIV Infection (AIDS Clinical Trials Group Protocol 360) 2003 ·Clinical Infectious Diseases ·Alejo Erice, C. Tierney, Martin Hirsch, Angela M. Caliendo, Adriana Weinberg, Michelle A. Kendall, Bruce Polsky	53

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact